BofA downgraded $NKE to Underperform, cutting its price target to $30 from $47.
The firm says Nike’s innovation continues to be overshadowed by pressure on its classics business. It now expects sales declines through FY27, versus its earlier expectation for a spring recovery.
BofA cut FY27 and FY28 EPS estimates by 11% and 12%, respectively, putting its FY27 estimate 14% below consensus.